花钱改基因，硅谷富豪开始定制「完美后代」

Core Viewpoint - The article discusses the controversial trend in Silicon Valley where elite individuals are using genetic screening technologies to select embryos based on desirable traits, including intelligence, leading to ethical concerns about eugenics and societal implications [4][14]. Group 1: Genetic Screening Technologies - The article outlines various genetic screening technologies, including PGT-M for single-gene disorders, PGT-A for aneuploidy, PGT-SR for chromosomal structural abnormalities, and PGT-P for polygenic disease risk assessment [6][8]. - PGT-P technology, which allows for the prediction of complex traits such as intelligence and physical appearance, has gained traction since the birth of the first baby using this method in 2020 [8][9]. Group 2: Emergence of Companies - Companies like Orchid and Herasight are at the forefront of offering embryo selection services based on intelligence, with claims of detecting IQ differences of up to 15 points among embryos [11][12]. - Nucleus Genomics has created a "gene store" where prospective parents can select from over 2,000 traits, including disease resistance and personality characteristics, raising ethical questions about commodifying human life [12][13]. Group 3: Ethical Implications - The article raises concerns about the potential societal impact of genetic selection, suggesting that if society begins to view genetic endowment as a determinant of personal ability and destiny, it could lead to a collapse of existing value systems [14][16]. - The narrative draws parallels to the film "Gattaca," which depicts a future where genetic selection creates a divide between the genetically elite and the underprivileged, emphasizing the risks of unchecked genetic engineering [13][14].